The accumulation of ERBB-2 in prostate cancer cells leads to the activation of signalling pathways, such as the phosphatidylinositol-3-kinase (PI3K)/AKT signalling pathway, which correlates with cancer progression and therapy resistance. Here, ERBB2 is linked to prostate carcinoma.